��ѧۧݧ�ӧ�� ާ֧ߧ֧էا֧�

��ѧۧݧ�ӧ�� ާ֧ߧ֧էا֧� - ��֧էѧܧ�ڧ��ӧѧ�� - /home/rickpfrv/tie.cx/uploads/cache/biolinks/Files/ab/9b/ab9b9975d44803fedcea3612b09545bc.txt

��ѧ٧ѧ�
a:6:{s:1:"k";s:41:"link?url=651fc7ff3a3ca834840ab62a9d5fe14d";s:1:"d";O:8:"stdClass":16:{s:7:"link_id";i:700;s:10:"project_id";N;s:7:"user_id";i:709;s:10:"biolink_id";N;s:9:"domain_id";i:0;s:10:"pixels_ids";s:2:"[]";s:4:"type";s:7:"biolink";s:7:"subtype";N;s:3:"url";s:12:"antoniolitch";s:12:"location_url";N;s:6:"clicks";i:3;s:8:"settings";s:4552:"{"title":"Retrospective Analysis Probing the Efficacy and Manageability of Tretinoin Gel 0.025% for Managing Acne Vulgaris","description":"Summary: This observational study evaluated the efficacy and tolerability of tretinoin gel 0.025% in a real-world setting among patients with acne vulgaris. Information was collected in hindsight from patient dossiers at a skin clinic during a 12-month interval. The key outcome metrics consisted of shifts in acne lesion tallies (inflammatory and non-inflammatory) and patient-documented acceptability. Data demonstrated a marked reduction in both inflammatory and non-inflammatory lesions after 12 weeks of regimen. Although starting irritation was frequent, it usually cleared up in the initial weeks. This study advocates for the persistent use of tretinoin gel 0.025% as a powerful and generally well-tolerated option for acne vulgaris in real-life clinic scenarios. Prologue: Acne vulgaris represents a frequent long-term inflammatory skin disorder impacting a large segment of the world's people, mainly teens and young adults. Treatment options vary widely, ranging from topical retinoids to oral antibiotics and systemic therapies. Tretinoin, serving as a topical retinoid, continues as a widely adopted and reliably established care for acne thanks to its proficiency in cutting sebum secretion, promoting epidermal cell change, and alleviating inflammation. Although many clinical studies have shown the effectiveness of tretinoin, practical observational research is essential to evaluate its performance and acceptability in varied patient groups and in standard medical practice settings. This investigation sought to retroactively review the clinical findings and acceptability of tretinoin gel 0.025% in patients with acne vulgaris managed at a dermatology center. Approaches: This retroactive observational analysis covered adult patients (18 and over) recognized with acne vulgaris who were assigned tretinoin gel 0.025% as the principal therapy modality between January 1, 2022, and December 31, 2022, at a single dermatology clinic. Patient records were examined to gather information on demographics (age, gender), baseline acne intensity (evaluated via a modified Global Acne Grading System [mGAGS]), therapy length, alterations in lesion numbers (inflammatory and non-inflammatory) at starting point, 4 weeks, 8 weeks, and 12 weeks, and patient-noted tolerance (evaluated through doctor notes recording patient issues). Data regarding simultaneous treatments were also captured. The mGAGS index was figured by summing the ratings for inflammatory lesions (papules, pustules, nodules, cysts) and non-inflammatory lesions (comedones). Each type of lesion was allocated a score depending on its seriousness and quantity. Tolerability was assessed based on clinician documentation of patient-reported adverse events, including dryness, irritation, erythema, and peeling. The seriousness of these side effects was grouped as mild, moderate, or severe. Statistical analysis was undertaken utilizing descriptive statistics to condense the demographic and clinical characteristics of the study participants. Paired t-tests were employed to evaluate lesion tallies at baseline and at each monitoring point. Changes in lesion counts were also analyzed using repeated measures ANOVA. The connection between starting acne seriousness and treatment response was gauged using correlation review. Data: A total of 100 patients (62 females, 38 males) with a mean age of 24.5 \u00b1 5.2 years were included in the study. The mean initial mGAGS index was 18.7 \u00b1 6.3. At baseline, the mean number of inflammatory lesions was 9.2 \u00b1 4.1 and the mean number of non-inflammatory lesions was 9.5 \u00b1 3.8. Significant reductions in both inflammatory and non-inflammatory lesion counts were observed at all follow-up time points compared to baseline (p","display_verified":false,"image":"","background_type":"preset","background":"three","text_color":"#fff","socials_color":"#fff","display_branding":false,"branding":{"name":"","url":""},"seo":{"block":false,"title":"Retrospective Analysis Probing the Efficacy and Manageability of Treti","meta_description":"","image":""},"utm":{"medium":"","source":""},"socials":{"email":"","tel":"","telegram":"","whatsapp":"","facebook":"","facebook-messenger":"","instagram":"","twitter":"","tiktok":"","youtube":"","soundcloud":"","linkedin":"","spotify":"","pinterest":""},"font":"karla","password":null,"sensitive_content":false,"leap_link":""}";s:10:"start_date";N;s:8:"end_date";N;s:10:"is_enabled";i:1;s:8:"datetime";s:19:"2025-11-05 21:06:11";}s:1:"g";a:1:{i:0;s:11:"link_id=700";}s:1:"e";O:8:"DateTime":3:{s:4:"date";s:26:"2025-11-14 01:17:01.749560";s:13:"timezone_type";i:3;s:8:"timezone";s:3:"UTC";}s:1:"m";N;s:1:"c";N;}

| ver. 1.4 | Github | . | PHP 7.4.33 | ��֧ߧ֧�ѧ�ڧ� ��ѧߧڧ��: 0.68 | proxy | phpinfo | ��ѧ��ۧܧ�